Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hannah Daniel

Having recently joined the team in 2022, Hannah Daniel is a consumer health reporter for Pharma Intelligence’s Health, Beauty, and Wellness publication.

Latest From Hannah Daniel

USANA Lowers Guidance After 15% Q1 Sales Drop; Mannatech Reports Nearly $1M Undelivered Goods

Due to uncertainty in COVID-19 landscape in China, USANA adjusted its 2022 fiscal year guidance. Direct seller Mannatech decreased its number of fulfilled orders by 6% in the first quarter.

Companies Sales & Earnings

ChromaDex TV Ads Increase Sales, Customer Base

Tru Niagen sales made up more than 85% of first-quarter total, and TV ads launched in March drove a “dramatic increase” in customers, says CEO Robert Fried.

Sales & Earnings Launches

Familiar Leadership For J&J's Planned Consumer Spinoff

J&J's current consumer health division head, Thibaut Mongon, will be at the helm of its planned spinout of the business while Paul Ruh will move to the company was CFO. 

Executive Changes Leadership

Bausch + Lomb Separates From Bausch Health After Delivering Its Only First-Quarter Sales Growth

Bausch Health closed Bausch + Lomb IPO offering 10% of shares instead of 20% planned. Bausch + Lomb’s $889m Q1 revenue up 1% while other Bausch Health divisions slumped.

Over The Counter 9 May 2022: The Landscape Of Naloxone Access With HRT’s Michael Hufford

In this episode, HBW Insight speaks to Michael Hufford, co-founder and CEO of Harm Reduction Therapeutics about the inaccessibility in the US of naloxone, a life-saving opioid overdose antidote. Hufford unpacks the history of naloxone access and explains why standing orders aren’t as helpful as they seem. We also explore the incentives for companies currently producing prescription naloxone to make the switch to OTC status, and why many of them have chosen not to. While the financial incentive may not be there, the public health need is dire, and Hufford explains the importance of harm reduction groups and non-profit pharmaceutical companies for getting naloxone into the hands of those who need it the most.

US States Health

Prestige Consumer Supply Chain Prowess Helps Offset Inflationary Pressures For Record Results

After a company-record FY2022, Prestige CEO Ron Lombardi says future inflationary pressures and supply chain issues should be “manageable.”

Sales & Earnings Companies
See All
UsernamePublicRestriction

Register